Literature DB >> 10685632

Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma.

Y Oda1, A Sakamoto, T Saito, N Kinukawa, Y Iwamoto, M Tsuneyoshi.   

Abstract

The hepatocyte growth factor (HGF)/c-MET signaling system plays an important role in the carcinogenesis of various organs. We investigated the expression of HGF and its receptor c-MET by immunohistochemistry (IHC) in 69 cases of synovial sarcoma and compared the findings with clinicopathologic parameters, proliferating activities evaluated by MIB-1 labeling index (MIB-1 LI), and patients' prognosis. Furthermore, mRNA analysis of HGF, c-MET, and SYT-SSX fusion gene was performed by reverse transcriptase-polymerase chain reaction (RT-PCR) in 22 concordant frozen materials. Twenty-one of 69 (30.4%) tumors showed positive reaction for c-MET, whereas 22 tumors (31.9%) were positive for HGF. In 10 cases, co-expression of HGF and c-MET was observed; however, there was no significant correlation between HGF and c-MET expression. HGF expression was correlated with female patients, large tumors (more than 5 cm), the presence of rhabdoid cells, low frequency of mast cells (<20/10 HPF), high nuclear grade (grade III), and high American Joint Committee (AJC) stage (III and IV). Conversely, c-MET expression was only correlated with large tumors. However, the coexpression of HGF and c-MET was significantly correlated with large tumor size, the existence of rhabdoid cells, and high AJC stage. Both the expression of HGF and the co-expression of HGF and c-MET showed a significantly high MIB-1 LI and were correlated with poor prognosis according to univariate analysis. Multivariate Cox analysis showed that high AJC stage, the expression of HGF, and a high MIB-1 LI (12.0>) independently had a negative impact on overall survival. In 22 frozen material cases evaluated by both IHC and RT-PCR, a statistically significant correlation was found between the 2 techniques. SYT-SSX fusion transcripts were detected in all 22 cases. Three tumors had SYT-SSX2 fusion transcripts, whereas 19 had SYT-SSX1 phenotype. Our results suggest that HGF/c-MET paracrine signaling may contribute to tumorigenesis and progression in synovial sarcoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10685632     DOI: 10.1016/s0046-8177(00)80218-x

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  22 in total

1.  A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:  James I Geller; John P Perentesis; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Elizabeth Fox; Susan M Blaney; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2017-04-27       Impact factor: 3.167

2.  Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth.

Authors:  Erin B Dickerson; Kevin Marley; Wade Edris; Jeffrey W Tyner; Vidya Schalk; Valerie Macdonald; Marc Loriaux; Brian J Druker; Stuart C Helfand
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

3.  Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.

Authors:  Keila E Torres; Quan-Sheng Zhu; Katelynn Bill; Gonzalo Lopez; Markus P Ghadimi; Xianbiao Xie; Eric D Young; Juehui Liu; Theresa Nguyen; Svetlana Bolshakov; Roman Belousov; Suizhau Wang; Guy Lahat; Jun Liu; Belinda Hernandez; Alexander J Lazar; Dina Lev
Journal:  Clin Cancer Res       Date:  2011-05-03       Impact factor: 12.531

Review 4.  Molecular classification of soft tissue sarcomas and its clinical applications.

Authors:  Shilpa Jain; Ruliang Xu; Victor G Prieto; Peng Lee
Journal:  Int J Clin Exp Pathol       Date:  2010-04-23

5.  Acute tissue injury activates satellite cells and promotes sarcoma formation via the HGF/c-MET signaling pathway.

Authors:  David Van Mater; Leonor Añó; Jordan M Blum; Micah T Webster; WeiQiao Huang; Nerissa Williams; Yan Ma; Diana M Cardona; Chen-Ming Fan; David G Kirsch
Journal:  Cancer Res       Date:  2014-12-12       Impact factor: 12.701

6.  MET overexpressing chordomas frequently exhibit polysomy of chromosome 7 but no MET activation through sarcoma-specific gene fusions.

Authors:  Florian Grabellus; Margarethe J Konik; Karl Worm; Sien-Yi Sheu; Johannes A P van de Nes; Sebastian Bauer; Werner Paulus; Rupert Egensperger; Kurt W Schmid
Journal:  Tumour Biol       Date:  2010-03-06

7.  Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?

Authors:  Elisabetta Pennacchioli; Giulio Tosti; Massimo Barberis; Tommaso M De Pas; Francesco Verrecchia; Claudia Menicanti; Alessandro Testori; Giovanni Mazzarol
Journal:  Clin Exp Metastasis       Date:  2012-06-15       Impact factor: 5.150

8.  Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-density.

Authors:  Cornelius Kuhnen; Thomas Muehlberger; Maria Honsel; Edina Tolnay; Hans Ulrich Steinau; Klaus-Michael Müller
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-09       Impact factor: 4.553

Review 9.  Antiangiogenic approaches for the treatment of advanced synovial sarcomas.

Authors:  Khanh Do; James H Doroshow; Shivaani Kummar
Journal:  Curr Opin Oncol       Date:  2012-07       Impact factor: 3.645

Review 10.  Molecular mechanisms underpinning sarcomas and implications for current and future therapy.

Authors:  Victoria Damerell; Michael S Pepper; Sharon Prince
Journal:  Signal Transduct Target Ther       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.